Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies

被引：1
作者：
Mousavi, Shahrzad [1 ]
Khazaee-Nasirabadi, Mohammad Hossein [2 ]
Seyedmehdi, Maryam Sadat [3 ]
Bazi, Ali [2 ,4 ]
Khalilabadi, Roohollah Mirzaee [2 ]
机构：
[1] Tarbiat Modares Univ, Fac Med Sci, Dept Hematol, Tehran, Iran
[2] Kerman Univ Med Sci, Fac Allied Med, Dept Hematol & Med Lab Sci, Kerman, Iran
[3] Shahid Beheshti Univ, Fac Life Sci & Technol, Dept Cell & Mol Biol, Tehran, Iran
[4] Zabol Univ Med Sci, Fac Allied Med Sci, Zabol, Iran
来源：
LEUKEMIA & LYMPHOMA | 2025年 / 66卷 / 04期
关键词：
Chimeric antigen receptor; CAR NK; NK; hematological malignancies; EX-VIVO EXPANSION; OFF-THE-SHELF; NK CELLS; T-CELLS; PERIPHERAL-BLOOD; LYMPHOCYTE SUBSETS; GENE-TRANSFER; NK-92; CELLS; LARGE-SCALE; LINE NK-92;
D O I：
10.1080/10428194.2024.2438802
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In recent times, the application of CAR-T cell treatment has significantly progressed, showing auspicious treatment outcomes in hematologic malignancies. However, along with these advances, certain limitations and challenges hurdle the widespread utilization of this technology. Recently, CAR-NK cells have gained attention in cancer treatment, as this approach has an important advantage over CART therapy (i.e. no need for HLA matching) for targeting foreign cells. This review aims to explore the benefits of CAR NK cell therapy, and generation strategies, as well as the challenges and limitations hindering the application of CAR NK cells in experimental studies and trials on hematologic malignancies.
引用
收藏
页码：594 / 616
页数：23
相关论文
共 218 条
[1]   Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9 [J].
Afolabi, Lukman O. ;
Adeshakin, Adeleye O. ;
Sani, Musbahu M. ;
Bi, Jiacheng ;
Wan, Xiaochun .
IMMUNOLOGY, 2019, 158 (02) :63-69
[2]   CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells [J].
Alcantara, Marion ;
Tesio, Melania ;
June, Carl H. ;
Houot, Roch .
LEUKEMIA, 2018, 32 (11) :2307-2315
[3]   Autologous lymphapheresis for the production of chimeric antigen receptor T cells [J].
Allen, Elizabeth S. ;
Stroncek, David F. ;
Ren, Jiaqiang ;
Eder, F. ;
West, Kamille A. ;
Fry, Terry J. ;
Lee, Daniel W. ;
Mackall, Crystal L. ;
Conry-Cantilena, Cathy .
TRANSFUSION, 2017, 57 (05) :1133-1141
[4]   Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor [J].
Amirache, Fouzia ;
Levy, Camille ;
Costa, Caroline ;
Mangeot, Philippe-Emmanuel ;
Torbett, Bruce E. ;
Wang, Cathy X. ;
Negre, Didier ;
Cosset, Francois-Loic ;
Verhoeyen, Els .
BLOOD, 2014, 123 (09) :1422-1424
[5]  
Antony GK, 2010, CURR MED CHEM, V17, P3297
[6]   Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM) [J].
Bachanova, Veronika ;
McKenna, David H. ;
Luo, Xianghua ;
DeFor, Todd E. ;
He, Fiona ;
Janakiram, Murali ;
Warlick, Erica D. ;
Wangen, Rose ;
Cayci, Zuzan ;
Grzywacz, Bartosz ;
Brachya, Guy ;
Peled, Tony ;
Miller, Jeffrey S. .
BLOOD, 2019, 134
[7]   A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS) [J].
Bachier, Carlos ;
Borthakur, Gautam ;
Hosing, Chitra ;
Blum, William ;
Rotta, Marcello ;
Ojeras, Paulius ;
Barnett, Brian ;
Rajangam, Kanya ;
Majhail, Navneet S. ;
Nikiforow, Sarah .
BLOOD, 2020, 136
[8]   Gene editing for immune cell therapies [J].
Bailey, Stefanie R. ;
Maus, Marcela V. .
NATURE BIOTECHNOLOGY, 2019, 37 (12) :1425-1434
[9]   Next-generation cell therapies: the emerging role of CAR-NK cells [J].
Basar, Rafet ;
Daher, May ;
Rezvani, Katayoun .
BLOOD ADVANCES, 2020, 4 (22) :5868-5876
[10]   Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer [J].
Batchu, Ramesh B. ;
Gruzdyn, Oksana V. ;
Tavva, Pavan S. ;
Kolli, Bala K. ;
Dachealli, Rajesh ;
Weaver, Donald W. ;
Gruber, Scott A. .
SURGERY, 2019, 166 (04) :503-508
12345678910